OSRHOSR Holdings Inc

OSR Holdings shares surged 41.28% after securing a global exclusive licensing deal for its Phase 3-ready cancer immunotherapy VXM01, with potential milestone payments up to $815 million.read more...

Woori IO, an OSR Company, Signs NDA with Sinopharm for China Market and Global Multicenter Trials Woori IO, an OSR Company, Signs NDA with Sinopharm for China Market and Global Multicenter Trials PR...

The company received an additional 180-day extension from Nasdaq to regain compliance after receiving an initial notice on Sept. 9, 2025.

Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical Wearables as a Catalyst for Accelerated Commercial Launch Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical...

Vaximm Appoints Sbastien Wieckowski, PhD, as Chief Scientific Officer to Advance Next-Generation Oral Immunotherapy Platform Vaximm Appoints Sbastien Wieckowski, PhD, as Chief Scientific Officer to...

Vaximm, an OSR Company, Receives Binding Term Sheet from BCM Europe for Global Exclusive License of VXM01 with $30M Upfront and Up to $815M in Milestones Vaximm, an OSR Company, Receives Binding Term...

Woori IO Shareholders Approve Share Exchange to Become Wholly-Owned Subsidiary of OSR Holdings Woori IO Shareholders Approve Share Exchange to Become Wholly-Owned Subsidiary of OSR Holdings PR...

Vaximm AG, an OSR Company, Updates Term Sheet with BCM Europe to Shorten Exclusivity Period to Three Months Vaximm AG, an OSR Company, Updates Term Sheet with BCM Europe to Shorten Exclusivity Period...

OSR Holdings to Present at the Emerging Growth Conference on December 10, 2025 OSR Holdings to Present at the Emerging Growth Conference on December 10, 2025 PR Newswire BELLEVUE, Wash., Dec. 1, 2025...